Streetbeat News

AZNCF

Astrazeneca plc

https://www.astrazeneca.com/home

CEO

Pascal Soriot

Employees

83,100

Industry

Pharmaceutical Preparation Manufacturing

Open

123.80

Mkt cap

196B

Volume

10

High

126.56

P/E Ratio

30.64

52-wk high

175.00

Low

123.80

Div yield

0.02

52-wk low

118.16

China's National Medical Products Association has approved AstraZeneca's Fasenra (Benralizumab) for the maintenance treatment of severe eosinophilic asthma in patients aged 12 and older.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 8:58 am

The FDA has approved AstraZeneca's Imfinzi (Durvalumab) in combination with chemotherapy for the treatment of resectable early-stage non-small cell lung cancer (NSCLC) without known EGFR mutations or ALK rearrangements. This approval could potentially expand the market for Imfinzi and improve AstraZeneca's revenue from oncology drugs.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 9:18 am

The FDA has accepted AstraZeneca's supplemental biologics license application for Imfinzi (Durvalumab) under priority review for limited-stage small cell lung cancer. The Prescription Drug User Fee Act date is anticipated during the fourth quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 8:55 am

The European Union has approved AstraZeneca's Imfinzi (Durvalumab) and Lynparza (Olaparib) for certain patients with primary advanced or recurrent endometrial cancer. The approval includes Imfinzi plus chemotherapy as a 1st-line treatment followed by Lynparza and Imfinzi for patients with mismatch repair proficient (pMMR) disease, and Imfinzi plus chemotherapy followed by Imfinzi alone for patients with mismatch repair deficient (dMMR) disease.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 9:42 am

China has approved Beyfortus (Nirsevimab), a long-acting monoclonal antibody developed by AstraZeneca and Sanofi, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection in neonates and infants. The treatment is expected to be available for the 2024-2025 RSV season.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 8:29 am

China has granted approval to AstraZeneca's Imfinzi (Durvalumab) for use as a first-line treatment for locally advanced or metastatic biliary tract cancer in combination with chemotherapy drugs Gemcitabine and Cisplatin.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 9:53 am

AztraZeneca's Tagrisso plus chemotherapy has extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in the FLAURA2 Phase 3 trial. The trial included patients with locally advanced or metastatic non-small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:31 am

AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan combined with Imfinzi, with or without chemotherapy, showed objective response rates of 77% and 50% and disease control rates of 92% and 93% respectively in untreated lung cancer patients. The trial included patients with previously untreated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:29 am

The FDA has issued a Complete Response Letter (CRL) to AstraZeneca regarding its Supplemental Biologics License Application for Ultomiris (Ravulizumab-cwvz) for Neuromyelitis Optica Spectrum Disorder patients. The FDA did not request additional analysis of the Phase 3 trial data and did not raise concerns about the efficacy or safety data. However, it requested modifications to enhance the Ultomiris Risk Evaluation and Mitigation Strategy.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 8:24 am

AstraZeneca has released its Q2 earnings and announced the discontinuation of several pipeline programs, including a Phase 2 study for hematological malignancies and a Phase 1 asset in cardiovascular disease. The company cited 'strategic portfolio prioritization' as the reason for these decisions. Despite this, AstraZeneca's CEO expressed optimism about interim data from a key lung cancer drug trial. The company's shares are up 4.36%.

Portfolio Pulse from Vandana Singh

July 28, 2023 | 5:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.